Introduction Molnupiravir (MOV) is an oral antiviral for the treatment of individuals with mild-
to-moderate COVID-19 and at high risk of progression to severe disease. Our objective was …

Background The real-world effectiveness of molnupiravir (MOL) during the dominance of
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …

Ever since the emergence of the SARS-CoV-2 pandemic, the quest for efficacious
therapeutic interventions has become a focal point of international health research, focusing …

Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …

Molnupiravir (MOV) was introduced in Israel in January 2022 during the SARS-CoV-2
Omicron surge for high-risk patients contraindicated for nirmatrelvir/ritonavir. This …

Background Real-world evidence on the effectiveness of oral antivirals in mild-to-moderate
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …

It is unclear whether molnupiravir has a beneficial effect on vaccinated patients infected with
the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
coronavirus disease 2019 (COVID-19), has radically altered daily life. Effective antiviral …

Background Clinical benefit of molnupiravir (MPV) in coronavirus disease 2019 (COVID-19)–
infected subpopulations is unclear. Methods We used a matched cohort study design to …

Background: COVID-19, first detected in Wuhan, China, has evolved into a lifethreatening
pandemic spread across six continents, with the global case count being more than 243 …